Immunogenic peptides comprising a T-helper epitope and a...

Details Immunogenic peptides comprising a T-helper epitope and a... Immunogenic peptides comprising a T-helper epitope and a...

2006-12-26

2006-12-26

Stucker, Jeffrey (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S188100, C424S202100, C424S204100, C424S208100, C424S278100, C530S324000, C530S826000

Reexamination Certificate

active

07153509

ABSTRACT:
The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method.

REFERENCES:
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5019387 (1991-05-01), Haynes et al.
patent: 5352576 (1994-10-01), Haynes et al.
patent: 5516632 (1996-05-01), Palker et al.
patent: 5643756 (1997-07-01), Kayman et al.
patent: 5800822 (1998-09-01), Sia et al.
patent: 5993819 (1999-11-01), Haynes et al.
patent: 6114143 (2000-09-01), Eda et al.
patent: 2001/0003646 (2001-06-01), Haynes et al.
patent: 2001/0036461 (2001-11-01), Haynes et al.
patent: 2002/0086283 (2002-07-01), Haynes et al.
patent: 2003/0147888 (2003-08-01), Haynes et al.
patent: 2004/0001851 (2004-01-01), Haynes et al.
patent: 2004/0039172 (2004-02-01), Haynes et al.
patent: 2004/0086506 (2004-05-01), Haynes et al.
patent: 2004/0132010 (2004-07-01), Haynes et al.
patent: 2004/0197344 (2004-10-01), Haynes et al.
patent: WO 93/15750 (1993-08-01), None
patent: WO 95/29700 (1995-11-01), None
patent: WO 97/14436 (1997-04-01), None
patent: WO 01/56355 (2001-08-01), None
patent: WO 02/24149 (2002-03-01), None
patent: WO 03/039470 (2003-05-01), None
patent: WO 03/046137 (2003-06-01), None
patent: WO 2004/009785 (2004-01-01), None
patent: WO 2004/075850 (2004-09-01), None
patent: WO 2005/016952 (2005-02-01), None
Pang et al. “HIV-1 env sequence variation in brain tissue of patients with AIDS-related neurologic disease”, J. Acquir. Immune Defic. Syndr., vol. 4, No. 11 (1991), pp. 1082-1092.
Haynes et al, HIV Vaccine Development at Duke University Medical Center , Immunologic Research 22(2-3):263-269 (2000).
Bartlett et al, “Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen”, AIDS 12(11):1291-1300 (1998).
De Berardinis et al, “Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses”, Nature Biotechnology 18:873-876 (2000).
U.S. Provisional Appl. No. 60/503,460 filed Sep. 17, 2003 and U.S. Provisional Appl. No. 60/604,722 filed Aug. 27, 2004 (see attached copy of PCT/US04/30397 filed Sep. 17, 2004).
U.S. Appl. No. 10/518,523 filed Dec. 21, 2004 (U.S. National Phase of WO 2004/009785 see above).
U.S. Appl. No. 10/973,977 filed Oct. 27, 2004.
U.S. Appl. No. 10/973,475 filed Oct. 27, 2004.
U.S. Provisional Appl. No. 60/625,720 filed Nov. 8, 2004.
Haynes et al, “HIV type 1 V3 region primer-Induced antibody suppresion is overcome by administration of C4-V3 peptides as a polyvalent immunogen”, AIDS Research and Human Retrovirises 11(2):211-221 (1995).
Spicer et al, “Modification of anti-HIV antibody response and peptide solution conformations by point substitutions in chimeric gp120 C4-V3 immunogenic peptides”, Abstrates of Papers America Chemical Society 218(1-2):MEDI 286 (1999) -XP009052973.

Affiliated with

Also associated with

Rating

Immunogenic peptides comprising a T-helper epitope and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunogenic peptides comprising a T-helper epitope and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic peptides comprising a T-helper epitope and a... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3717997